La Merie Publishing: Market Research Reports

Competitor Analysis: Inhibitors of Negative Immune Checkpoints CTLA-4, LAG-3, TIM-3 & Others This Competitive Intelligence report about Inhibitors of Negative Immune Checkpoints CTLA-4, LAG-3, TIM-3 & Others evaluates ... comments with a hyperlink leading to the source of information. About Competitor Analysis Series: The Competitor Analysis Series delivers NO-FRILLS, but concise information about the ...

Anti-Her2 Antibody-Drug Conjugates in: September 2016 R&D and Business Tracker for Antibody-Drug Conjugates This pdf report contains information about Antibody-Drug Conjugates (ADCs) released during the month of September 2016. This ... for Antibody-Drug Conjugates. Featured presentations of September 2016 include the pipeline of Her2-targeted antibody-drug conjugates, the profile of Swiss biotech NBE Therapeutics and the profile of anti-Her2 antibody-drug conjugate MEDI4276 ...

CD123-Targeted Immunotherapeutics in: September 2016 R&D and Business Tracker for Bispecific Antibodies This pdf report contains information about Bispecific Antibodies released during the month of September 2016. This issue forms part of the subscription service R&D and Business Tracker for Bispecific Antibodies. Featured presentations of September 2016 include the pipeline of CD123-targeted immunotherapeutics ...

CD33-Targeted Immunotherapeutics in: September 2016 R&D and Business Tracker for TCR & CAR T-Cells and NK Cells ... TCR & CAR T-Cells and NK Cells Featured presentations of September 2016 include the pipeline of CD33-targeted immunotherapeutics, the profile of US biotech Eureka Therapeutics and the profile ...

Competitor Analysis: NGF-TrkA Pathway Agonists & Antagonists 2016 This Competitive Intelligence report about NGF-TrkA Pathway Agonists & Antagonist provides a competitor evaluation in the field of recombinant antibodies, proteins and small molecules acting as antagonists or agonists of NGF or its high affinity receptor TrkA ...

Competitor Analysis Immunotoxins 2016 This Competitive Intelligence report about Immunotoxins provides a competitor evaluation in the field of recombinant fusion proteins of a mainly antibody-based ... comments with a hyperlink leading to the source of information. About Competitor Analysis Series: The Competitor Analysis Series delivers NO-FRILLS, but concise information about the ...

TCR & CAR Engineered T-Cell and NK Cell Therapeutics 2016: Convergence of technologies opens business opportunities beyond CD19 CARTs The report TCR & CAR Engineered T-Cell and NK Cell Therapeutics 2016: Convergence of technologies ... ; Engineered TCR T-cells, including TCR target discovery; The current status of DLIs, CTLs and TILs; Manufacturing of T-cells for adoptive cell therapy; NK cells and CAR engineered NK cells; International perspective on TCR & CAR T-cell and NK cell ...

... Cell Maturation Antigen (BCMA): hot target for emerging treatment modalities The highly restricted expression of B-cell maturation antigen (BCMA) to plasma cells and its role in the survival and growth for multiple myeloma cells makes BCMA a good potential target ...

CD123: a paradigmatic target for immunotherapeutic treatment modalities This report describes and evaluates the competitive landscape of CD123-targeted immunotherapeutics based on different treatment modalities. CD123, or the ... -CD123 Immunotherapeutics Clinical Experience with CD123-Targeted Treatment Modalities Target and Treatment Modality Safety Concerns of anti-CD123 Immunotherapeutics Competitive Landscape Profiles of Anti-CD123 Immunotherapeutics ...

Competitor Analysis: Bispecific Antibodies for Cancer, Inflammatory Other Diseases This Competitive Intelligence report about Bispecific Antibodies for Cancer, Inflammatory Other Diseases evaluates the competitive ... as: T-Cell or NK cell redirecting bispecific cancer antibodies Bispecific immuno-oncology antibodies Bispecific tumor antigens targeted cancer antibodies Bispecific antibodies for inflammatory autoimmune diseases Bispecific antibodies for cardiometabolic, infectious, neurologic ...

Competitor Analysis: Clostridium Difficile Vaccines and Therapeutics 2016 This Competitive Intelligence Report about prophylaxis and therapy of Clostridium difficile infections provides a competitor evaluation in the field of new molecules ... for prevention and  treatment of Clostridium difficile infections. In addition, the report lists company-specific R&D pipelines of C. difficile vaccines and therapeutics. Competitor projects are listed in a tabular ...

... T-cell or natural killer (NK) cells redirecting bispecific antibodies has increased from 4 to 21 and further 16 molecules could enter clinical development within the next 12 months. This report T-Cell Redirecting Bispecific Antibodies 2016: A competitive landscape analysis of stakeholders, technologies, pipelines and deals “ as of May 2016 brings you up-to-date information ...

Competitor Analysis: Biosimilar & Biosuperior Therapeutic Antibodies – 2016 Update This Competitive Intelligence report about Biosimilar & Biosuperior Therapeutic Antibodies updates the competitive landscape of biosimilar therapeutic antibodies as of May 2016. The report evaluates the the first wave of biosimilar ...

Competitor Analysis: Biosimilar and Biosuperior Anti-CD20 Antibodies – 2016 Update This Competitive Intelligence Report about Biosimilar and Biosuperior Anti-CD20 Antibodies 2016 updates the ... comments with a hyperlink leading to the source of information. About Competitor Analysis Series: The Competitor Analysis Series delivers NO-FRILLS, but concise information about the ...

Competitor Analysis: Biosimilar and Biosuperior Anti-EGF-R Antibodies - 2016 Update This Competitive Intelligence report about Biosimilar and Biosuperior Anti-EGF-R Antibodies updates the competitive ... comments with a hyperlink leading to the source of information. About Competitor Analysis Series: The Competitor Analysis Series delivers NO-FRILLS, but concise information about the ...

Competitor Analysis: Biosimilar and Biosuperior Anti-Her2 Antibodies – 2016 Update This Competitive Intelligence Report about Biosimilar and Biosuperior Anti-Her2 Antibodies 2016 updates the ... comments with a hyperlink leading to the source of information. About Competitor Analysis Series: The Competitor Analysis Series delivers NO-FRILLS, but concise information about the ...

Competitor Analysis: Biosimilar and Biosuperior Anti-TNF Antibodies – 2016 Update Humira, Enbrel and Remicade ... comments with a hyperlink leading to the source of information. About Competitor Analysis Series: The Competitor Analysis Series delivers NO-FRILLS, but concise information about the ...

... about Biosimilar & Biosuperior Therapeutic Antibodies updates the competitive landscape of biosimilar therapeutic antibodies as of May 2016. The report evaluates the the first wave of biosimilar ... , pavilizumab, tocilizumab, and ustekinumab. Download sample pages of Competitor Analysis: Biosimilar & Biosuperior Therapeutic Antibodies – 2016 Update Competitor projects are listed in a tabular format providing information ...

Antibody Target, Technology & Pipeline Database: 1-Year Subscription Therapeutic monoclonal antibodies have become a clinically and commercially successful class of drugs. Branded therapeutic antibodies on the market reached ... of the Antibody Target, Technology & Pipeline Database. Credentials to access the database will be sent by e-mail within 24 hours after purchase. Benefits from the Antibody Pipeline Database: Intuitive ...

Competitor Analysis: CD19-Targeted Therapeutics – 2016 Update This Competitive Intelligence report about CD19-Targeted Therapeutics provides a competitor evaluation in the field of antibody- and T-cell-based therapeutics for the treatment ... T-cells targeting CD19. In addition, the report lists company-specific R&D pipelines of CD19-Targeted Therapeutics. Competitor projects are listed in a tabular format providing information on: Drug Codes, Target / Mechanism ...

RORgamma Modulators 2016: A comparative analysis of the landscape of RORgamma antagonists and agonists Retinoic acid-related orphan nuclear receptor gamma (RORgamma) is a hot, but difficult-to-drug target ... from start of a discovery program of RORgamma modulators until entry into human studies are calculated. The competitive landscape of RORgamma modulator development and discovery projects ...

Competitor Analysis: Anti-VEGF/R Biosimilars and Biosuperiors of Avastin, Cyramza, Eylea and Lucentis – a 2016 Update The Competitive Intelligence Report Anti-VEGF/R Biosimilars and Biosuperiors of Avastin, Cyramza, Eylea and Lucentis – a 2016 Update“ provides a competitor evaluation in the field ...

Competitor Analysis: Dengue Virus Vaccines, Antibodies & Antivirals This Competitive Intelligence Report provides a competitor evaluation in the field of approved and investigational vaccines and therapeutics against one or more ... Dengue virus for prophylaxis of Dengue fever and of therapeutics for treatment of Dengue fever. In addition, the report lists company-specific R&D pipelines of Dengue Virus Vaccines, Antibodies and Antivirals. Competitor ...

Competitor Analysis: Flavivirus Vaccines: Zika, Dengue, Chikungunya, West Nile, Yellow Fever, Japanese Encephalitis & Tick-Borne Encephalitis Virus Vaccines The Competitive Intelligence Report Flavivirus Vaccines: Zika, Dengue, Chikungunya, West Nile, Yellow Fever, Japanese Encephalitis & Tick-Borne Encephalitis Virus Vaccines“ provides a competitor ...

Competitor Analysis: PTH Receptor Agonists 2016 and Teriparatide Biosimilars and Biosuperiors This Competitive Intelligence report titled PTH Receptor Agonists 2016 and Teriparatide Biosimilars and Biosuperiors“ provides a competitor evaluation in the field of protein- and peptide-based agonists of the parathyroid hormone (PTH) receptor ...

Competitor Analysis: Inhibitors of the bromodomain and extra-terminal domain (BET) family The Competitive Intelligence Report Inhibitors of the bromodomain and extra-terminal domain (BET) family as of January 201 provides a competitor analysis in the development pipeline ...

... same number of ADC programs are in preclinical R&D. Download Samples Pages: Antibody-Drug Conjugates 2016: Perspectives & Opportunities - a Pipeline, Technology, Stakeholder & Business Analysis For the first ... entitled „Antibody-Drug Conjugates 2016: Perspectives & Opportunities - a Pipeline, Technology, Stakeholder & Business Analysis“ is based on the analysis of more than 90 companies, more than 100 ADC drug profiles ...

Competitor Analysis: Amyloid beta- and Tau-Targeted Antibodies & Vaccines The Competitive Intelligence Report Amyloid beta- and Tau-Targeted Antibodies & Vaccines as of September 2015 provides a competitor analysis in the ... , the report lists company-specific R&D pipelines of amyloid beta- and tau-targeted antibodies & vaccines. Competitor projects are listed in a tabular format providing Information ...

Competitor Analysis: Interleukin-4/-13 (IL-4/-13) Inhibitors or Receptor Antagonists The Competitive Intelligence report about inhibitors of interleukin-4 (IL-4) and/or IL-13 and antagonists of the IL-4 or IL-13 receptor provides a competitor analysis of novel antibody molecules for treatment ...

Competitor Analysis: Sphingosine-1-Phosphate (S1P) Receptor Modulators The Competitive Intelligence report about sphingosine-1-phosphate (S1P) receptor modulators provides a competitor analysis of approved or novel S1P receptor modulators for treatment of inflammatory and autoimmune diseases such ...

Competitor Analysis: Interleukin-23 & IL-12/23 Antagonists The Competitive Intelligence report about Interleukin-23 (IL-23) and IL-12/23 antagonists provides a competitor analysis of approved or being developed novel antagonists of interleukin-23 and IL-12/23 (p40 subunit) for ... comments with a hyperlink leading to the source of information. About Competitor Analysis Series: The Competitor Analysis Series delivers NO-FRILLS, but concise information about the ...

Competitor Analysis: Interleukin-17/Receptor (IL-17/R) Antagonists The Competitive Intelligence report about Interleukin-17 (IL-17) inhibitors and IL-17 receptor IL-17R) antagonists provides a competitor analysis as of August 2015 in the development pipeline of novel inhibitors and antagonists of IL-17 and ...

Filgrastim & Pegfilgrastim Biosimilars & Biosuperiors 2015 – a G-CSF & GM-CSF Competitor Analysis The Competitive Intelligence report Filgrastim & Pegfilgrastim Biosimilars & Biosuperiors 2015 – a G-CSF & GM-CSF Competitor Analysis describes product ... G-CSF products represent an attractive market size for biosimilar proteins in regulated markets. Biosimilar filgrastim products have already been introduced into the the ...

Competitor Analysis: The rapeutic Antibodies 2015: Biosimilars & Biosuperiors This Competitive Intelligence Report about The rapeutic Antibodies 2015: Biosimilars & Biosuperiors provides a competitor ...

Competitor Analysis: EGF-R Antibodies 2015 – Biosuperiors and Biosimilars of Erbitux This Competitive Intelligence Report about EGF-R Antibodies 2015 – Biosuperiors and Biosimilars of Erbitux provides a competitor evaluation in the field of recombinant antibodies targeting epithelial growth factor receptor (EGF-R) to treat solid tumors as of March 2015 ...

Competitor Analysis: CD20 Antibodies 2015 - Biosimilars and Biosuperiors of Rituximab This Competitive Intelligence Report about CD20 Antibodies 2015- Biosimilars and Biosuperiors of Rituximab provides a competitor evaluation in the field of recombinant antibodies targeting CD20 for treatment of B-cell mediated ...

Competitor Analysis: TNF Antibodies 2015– Biosimilars and Biosuperiors of Humira, Remicade and Enbrel The present Competitive Intelligence report about TNF Antibodies 2015– Biosimilars and Biosuperiors of Humira, Remicade and Enbrel provides a competitor evaluation in the field of recombinant antibodies targeting tumor necrosis factor (TNF) alpha ...

2014 Sales of Recombinant Therapeutic Antibodies & Proteins This Competitive Intelligence report prepared by La Merie Business Intelligence provides a compilation of the sales data of recombinant therapeutic proteins and antibodies in the calendar year 2014. Sales data were obtained from company publications ...

... Engineered TCR and CAR Immunotherapeutics 2015: A comparative analysis of the landscape of and business opportunities with  TCR and CAR antibodies, T cells, NK cells, TILs, DLIs & CTLs The engineered ... Cellular TCR T Cells CAR T Cells (autologous/allogeneic) Recombinant Bispecific TCR-anti-CD3 (e.g. ImmTACs) Bispecific antibodies (incl. anti-CD3) This report Engineered TCR and CAR Immunotherapeutics ...

... Competitor Analysis: IDO & TDO Inhibitors - Novel Immune Response Checkpoint Modulators The Competitive Intelligence report about IDO & TDO Inhibitors - Novel Immune Response Checkpoint Modulators provides a competitor analysis as of March 2015 in the development pipeline of novel inhibitors of indoleamine 2,3-dioxygenase (IDO) and ...

Competitor Analysis: Specific and Bispecific Her3 Antibodies This Competitive Intelligence Report about Specific and Bispecific Her3 Antibodies provides a competitor evaluation in the field of recombinant specific antibodies targeting Her3 or bispecific antibodies targeting Her3 and Her2 or EGF-R or other ...

Competitor Analysis: Her2 Antibodies 2015 - Biosimilars and Biosuperiors of Herceptin This Competitive Intelligence Report about Her2 Antibodies 2015 - Biosimilars and ... and make out about 81% of the franchise sale. Therefore, the Her2 antibody market is not only highly attractive for biosimilar developments ...

Competitor Analysis: VEGF & VEGF-R Antibodies 2015 – Biosimilars and Biosuperiors of Avastin and Lucentis This Competitive Intelligence Report about VEGF and VEGF-R ... more cancer and eye disease indications. The commercial success of the VEGF antibodies and the expiry of patent protection has laid the ground ...

... Competitor Analysis: Alpha Synuclein and LRRK2 Inhibitors - Novel Drug Candidates for Parkinson's Disease The Competitive Intelligence report about Alpha ... on inhibitors of the molecular targets alpha-synuclein and LRRK2 including small molecules, antibodies, vaccines and RNAi. Competitor projects are listed ...

Competitor Analysis: Nonalcoholic Steatohepatitis (NASH) – Novel Drug Candidates The Competitive Intelligence report about Nonalcoholic Steatohepatitis (NASH) - Novel Drug Candidates provides a competitor analysis in the development pipeline of novel therapeutics for treatment of NASH. Purchase of the pdf ...

Recombinant Coagulation Factors 2015: Maturation of recombinant clotting factor pipeline and emergence of gene therapy and alternative procoagulants A Pipeline ... coagulation factors Corporate profiles of all relevant stakeholders including deals and pipelines Pipeline and technology trends Download Sample Pages: Recombinant Coagulation Factors 2015 - Maturation of recombinant clotting factor pipeline ...

Peptide Therapeutics Pipeline Database: 1-Year Subscription Subscription to La Merie Publishing’s proprietary Peptide Therapeutics Pipeline Database provides online access to Peptide Therapeutics on the market and in research & development. The peptide segment database contains about 900 files. Each ...

Competitor Analysis: Cancer Peptides The Competitive Intelligence Report Cancer Peptides as of November 2014 provides a competitor analysis in the product portfolios and development pipeline of peptide therapeutics for treatment of cancer. Purchase of the pdf report includes a 6-month online access to the ...

Competitor Analysis: Cardiometabolic Peptides The Competitive Intelligence Report Cardiometabolic Peptides as of November 2014 provides a competitor analysis in the development pipeline of peptide therapeutics for treatment of diabetes, obesity and atherosclerosis. Purchase of the pdf report includes a 6- ...

Competitor Analysis: Ebola Virus Vaccines and Therapeutics The present Competitive Intelligence Report about prophylaxis and therapy of Ebola virus infections ... Ebola virus infections as of October 2014. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any ...